Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotech company focusing on AAV-based gene therapies for severe monogenic CNS diseases, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). On September 3, 2024, the company's Compensation Committee granted a new employee an option to purchase 311,000 shares of common stock. The stock option, issued under Taysha's 2023 Inducement Plan, has an exercise price of $2.06 per share, equal to the closing price on the grant date. The option has a 10-year term and will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting monthly over the following 36 months, subject to continued employment.
Taysha Gene Therapies (Nasdaq: TSHA), una compagnia biotech in fase clinica che si concentra su terapie geniche basate su AAV per gravi malattie monogeniche del sistema nervoso centrale, ha annunciato una concessione di indennità ai sensi della Regola di Quotazione Nasdaq 5635(c)(4). Il 3 settembre 2024, il Comitato Compensativo della compagnia ha concesso a un nuovo dipendente un'opzione per acquistare 311.000 azioni di azioni ordinarie. L'opzione, emessa nell'ambito del Piano di Indennità 2023 di Taysha, ha un prezzo di esercizio di 2,06 dollari per azione, pari al prezzo di chiusura alla data di concessione. L'opzione ha una durata di 10 anni e verrà maturata in quattro anni, con il 25% che matura al primo anniversario e il restante 75% che matura mensilmente nei successivi 36 mesi, soggetto a mantenimento dell'impiego.
Taysha Gene Therapies (Nasdaq: TSHA), una empresa biotecnológica en etapa clínica centrada en terapias génicas basadas en AAV para enfermedades monogénicas severas del SNC, ha anunciado una concesión de incentivo bajo la Regla de Cotización 5635(c)(4) de Nasdaq. El 3 de septiembre de 2024, el Comité de Compensación de la empresa concedió a un nuevo empleado una opción para comprar 311,000 acciones de acciones ordinarias. La opción sobre acciones, emitida bajo el Plan de Incentivo 2023 de Taysha, tiene un precio de ejercicio de 2.06 dólares por acción, igual al precio de cierre en la fecha de concesión. La opción tiene un plazo de 10 años y se consolidará en cuatro años, con el 25% consolidándose en el primer aniversario y el 75% restante consolidándose mensualmente durante los siguientes 36 meses, sujeto a la continuación del empleo.
Taysha Gene Therapies (Nasdaq: TSHA)는 심각한 단일 유전자 CNS 질환을 위한 AAV 기반 유전자 치료에 중점을 둔 임상 단계의 생명공학 회사로, Nasdaq 상장 규칙 5635(c)(4)에 따라 유인 보상을 발표했습니다. 2024년 9월 3일, 회사의 보상위원회는 신규 직원에게 311,000주의 일반 주식을 구입할 수 있는 옵션을 부여했습니다. Taysha의 2023년 유인 계획에 따라 발행된 주식 옵션은 부여일의 종가와 동일한 주당 2.06달러의 행사가격을 가지고 있습니다. 이 옵션은 10년의 기간을 가지며 4년 동안 차등적으로 발생하고, 첫 번째 기념일에 25%가 발생하며, 나머지 75%는 다음 36개월 동안 매달 발생합니다. 이는 계속 고용되었을 경우에만 해당됩니다.
Taysha Gene Therapies (Nasdaq: TSHA), une société biopharmaceutique en phase clinique axée sur les thérapies géniques basées sur AAV pour les maladies monogéniques sévères du système nerveux central, a annoncé une attribution d'incitation selon la règle de cotation Nasdaq 5635(c)(4). Le 3 septembre 2024, le comité de rémunération de l'entreprise a accordé à un nouvel employé une option d'achat de 311.000 actions ordinaires. L'option sur actions, émise dans le cadre du Plan d'incitation 2023 de Taysha, a un prix d'exercice de 2,06 dollars par action, équivalent au prix de clôture à la date d'attribution. L'option a une durée de 10 ans et sera acquise sur une période de quatre ans, avec 25% acquis lors du premier anniversaire et les 75% restants acquis mensuellement au cours des 36 mois suivants, sous réserve du maintien de l'emploi.
Taysha Gene Therapies (Nasdaq: TSHA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf AAV-basierte Gentherapien für schwere monogene Erkrankungen des zentralen Nervensystems konzentriert, hat eine Anreizgewährung gemäß der Nasdaq-Listing-Regel 5635(c)(4) bekannt gegeben. Am 3. September 2024 hat der Vergütungsausschuss des Unternehmens einem neuen Mitarbeiter eine Option zum Kauf von 311.000 Aktien des Stammkapitals gewährt. Die Optionsvereinbarung, die im Rahmen des Taysha 2023 Incentive Plans ausgegeben wurde, hat einen Ausübungspreis von 2,06 US-Dollar pro Aktie, der dem Schlusskurs am Tag der Gewährung entspricht. Die Option hat eine Laufzeit von 10 Jahren und wird über einen Zeitraum von vier Jahren fällig, wobei 25% nach einem Jahr und die verbleibenden 75% monatlich über die nächsten 36 Monate fällig werden, vorausgesetzt, das Arbeitsverhältnis besteht weiterhin.
- Attraction of new talent with stock options as incentive
- Alignment of employee interests with company performance through equity compensation
- Potential dilution of existing shareholders' equity
DALLAS, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 3, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 311,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price of
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
FAQ
What is the exercise price of the stock option granted by Taysha Gene Therapies (TSHA) on September 3, 2024?
How many shares of common stock are included in the option granted by Taysha Gene Therapies (TSHA) to the new employee?
What is the vesting schedule for the stock option granted by Taysha Gene Therapies (TSHA) on September 3, 2024?
Under which plan was the inducement grant issued by Taysha Gene Therapies (TSHA) on September 3, 2024?
